COVID Cure: DCGI approves Itolizumab for restricted emergency use
It is for the treatment of ‘cytokine’ release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19, they said.
New Delhi: India's drug regulator has approved Itolizumab, a medicine used to cure psoriasis for "restricted emergency use" to treat COVID-19 patients with moderate to severe acute respiratory distress, informed officials.
Dr V G Somani, approved monoclonal antibody injection Itolizumab, an already approved drug of Biocon for several years, for restricted emergency use. It is for the treatment of 'cytokine' release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19, they said.
"The approval was given after its clinical trials on COVID-19 patients in India was found satisfactory by the expert committee comprising pulmonologists, pharmacologists and medical experts from AIIMS, among others, for treatment of cytokine release syndrome," an official told PTI.
Written informed consent of each patient is required before the use of this drug, he said.
Read also: Serum Institute of India COVID vaccine anticipates DCGI nod by 2020 end
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.